- Wednesday, August 2, 2023
8:00 AM – 8:15 AM ET
Welcome
8:00 AM – 8:15 AM ET
WelcomeCo-Chair: – Vanderbilt-Ingram Cancer Center
Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Co-Chair###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Co-Chair: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Co-Chair###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Co-Chair: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### 8:15 AM – 8:30 AM ET
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant Immunotherapy
8:15 AM – 8:30 AM ET
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Neoadjuvant ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 8:30 AM – 8:45 AM ET
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant Immunotherapy
8:30 AM – 8:45 AM ET
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - Adjuvant ImmunotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 8:45 AM – 9:00 AM ET
1 - Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers
8:45 AM – 9:00 AM ET
Session 1: Debate: Neoadjuvant vs Adjuvant Immunotherapy for Locally Advanced HER-2 Positive Upper Gastrointestinal Tract (UGI) Cancers - DiscussionModerator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Moderator: – Vanderbilt-Ingram Cancer Center
Panelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Kansas University Cancer Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### 9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 9:30 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined Immunotherapy
9:15 AM – 9:30 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Neoadjuvant Combined ImmunotherapyPresenter: – Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Presenter###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 9:30 AM – 9:45 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - Chemotherapy
9:30 AM – 9:45 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - ChemotherapyPresenter: – Kansas University Cancer Center
Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Presenter###Associate Professor###Kansas University Cancer Center###Presenter: – Kansas University Cancer Center
### 9:45 AM – 10:00 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC)
9:45 AM – 10:00 AM ET
Session 2: Debate: Neoadjuvant Combined Immunotherapy vs Chemotherapy for MSI-H Locally Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (GAC/GEJAC) - DiscussionModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Panelist: – Memorial Sloan Kettering Cancer Center
Panelist: – Kansas University Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Yelena Y. Janjigian, MD – Memorial Sloan Kettering Cancer Center ### 1003985###Panelist###Chief, Gastrointestinal Oncology Service###Memorial Sloan Kettering Cancer Center###Panelist: – Memorial Sloan Kettering Cancer Center
### @@@ Anup Kasi, MD, MPH – Kansas University Cancer Center ### 1919511###Panelist###Associate Professor###Kansas University Cancer Center###Panelist: – Kansas University Cancer Center
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innvoation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:15 PM ET
Session 3: Targeted Agents in Colorectal Cancer: An UpdatePresenter: – University of Southern California
11:30 AM – 12:15 PM ET
Session 3: Targeted Agents in Colorectal Cancer: An UpdatePresenter: – University of Southern California
Heinz-Josef Lenz, MD – University of Southern California ### 989581###Presenter###Oncologist###University of Southern California###Presenter: – University of Southern California
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:15 PM ET
Session 4: Deciphering Appendiceal CancerPresenter: – Vanderbilt-Ingram Cancer Center
12:30 PM – 1:15 PM ET
Session 4: Deciphering Appendiceal CancerPresenter: – Vanderbilt-Ingram Cancer Center
Deepa Magge, MD, FACS – Vanderbilt-Ingram Cancer Center ### 1596159###Presenter###Assistant Professor of Surgery###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:30 PM ET
Non-CME Innvoation Theater
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM ET
Break
2:30 PM – 2:45 PM ET
Break
2:45 PM – 3:30 PM ET
Session 5: Clinical Trial Landscape Incorporating ctDNAPresenter: – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
2:45 PM – 3:30 PM ET
Session 5: Clinical Trial Landscape Incorporating ctDNAPresenter: – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
Pashtoon M. Kasi, MD, MS – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine ### 697458###Presenter###Director Colon Cancer Research; Director Liquid Biopsy Research###Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine###Presenter: – Weill Cornell Medicine/NewYork-Presbyterian; Englander Institute of Precision Medicine
### 3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
3:45 PM – 4:20 PM ET
6 - Session 6: Integration of Supportive Care
3:45 PM – 4:20 PM ET
Session 6: Integration of Supportive CarePresenter: – Memorial Sloan Kettering Cancer Center
Andrew Epstein, MD – Memorial Sloan Kettering Cancer Center ### 1880690###Presenter###Associate Attending###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 4:20 PM – 4:30 PM ET
6 - Live Q&A
4:20 PM – 4:30 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center
Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Memorial Sloan Kettering Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Moderator###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Moderator: – Vanderbilt-Ingram Cancer Center
### @@@ Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Andrew Epstein, MD – Memorial Sloan Kettering Cancer Center ### 1880690###Speaker###Associate Attending###Memorial Sloan Kettering Cancer Center###Speaker: – Memorial Sloan Kettering Cancer Center
### 4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
4:45 PM – 5:20 PM ET
7 - Session 7: Perspectives on Clinical Trial Development in Anal Cancer
4:45 PM – 5:20 PM ET
Session 7: Perspectives on Clinical Trial Development in Anal CancerPresenter: – Vanderbilt-Ingram Cancer Center
Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Presenter###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Presenter: – Vanderbilt-Ingram Cancer Center
### 5:20 PM – 5:30 PM ET
7 - Live Q&A
5:20 PM – 5:30 PM ET
Live Q&AModerator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Speaker: – Vanderbilt-Ingram Cancer Center
Jordan D. Berlin, MD – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center ### 697513###Moderator###Ingram Professor of Cancer Research###Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center###Moderator: – Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
### @@@ Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center ### 697457###Speaker###David H. Johnson Endowed Chair in Surgical and Medical Oncology, Co-Director, GI Oncology, Co-Leader, Gastrointestinal Cancer Research Program###Vanderbilt-Ingram Cancer Center###Speaker: – Vanderbilt-Ingram Cancer Center
###
